Thermo Fisher Scientific Inc. TMO
Composite 50/100; the shares have moved about 34% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 31/100 — a moderate mark against it.
Momentum ranks 70/100 — a moderate point in its favour. Balance-sheet strength ranks 59/100 — a slight point in its favour. Quality ranks 52/100 — a slight point in its favour.
Valuation ranks 31/100 — a moderate mark against it. Income ranks 36/100 — a moderate mark against it. Growth ranks 45/100 — a slight mark against it.
What the company does Thermo Fisher Scientific (TMO) supplies life-science reagents, instruments, and diagnostics to pharma, biotech, academic, and clinical labs. Its four segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services—span drug discovery, vaccine production, and clinical testing.
Key financials TMO posts 41% gross, 18.8% operating, and 15% net margins on 10.5% revenue growth and 9.4% EPS growth. ROE is 13.5%, ROA 5.1%, and ROCE 8.8%. Leverage is moderate (Debt/Equity 0.81), but interest coverage is 5.88x and current ratio 1.55x.
Stock health Momentum is strong: +33.81% over 3m, +10.87% over 6m, and +31.79% over 12m, though down 5.87% from its 52-week high. RSI(14) is 74.50, indicating overbought conditions. Sideravia scores TMO in the 31.1th valuation percentile and 49.6th overall.
Price vs fair value TMO trades at a discount of 4.40% to the analyst mean target of 631.42. - Reuters reports India customer growth of 15%-20% on biopharma research and manufacturing tailwinds. - Simply Wall St highlights a new FDA-cleared multiple myeloma platform. - Insider Monkey compares TMO to Danaher on positioning.
Looking forward Forward P/E of 22.47 and PEG of 0.59 suggest valuation support, but high trailing P/E (31.05) and EV/EBITDA (20.53) temper enthusiasm. Analysts expect continued growth in specialty diagnostics and biopharma services, though momentum indicators warn of near-term volatility.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.